Tumor Lysis Syndrome
Diagnosis and Pathophysiology
Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma.
Hande KR, Garrow GC.
Am J Med. 1993;94:133-139.
Description: Analysis of 102 patients with NHL to identify risk factors for the development of tumor lysis after chemotherapy. Elevated LDH and renal insufficiency are identified as markers of increased risk.
PubMed citation number: 8430709
Tumor lysis syndrome in small cell carcinoma and other solid tumors.
Kalemkerian GP, Darwish B, Varterasian ML.
Am J Med. 1997;103:363-367.
Description: Analysis of 25 patients with small-cell carcinoma or other solid tumors to identify risk factors for the development of tumor lysis syndrome. The authors conclude that TLS is infrequent in solid tumors, but that renal insufficiency, elevated LDH, and hyperuricemia are risk factors.
PubMed citation number: 9375703
Incidence and treatment of tumor lysis syndrome in patients with acute leukemia.
Razis E, Arlin ZA, Ahmed T, et al.
Acta Haematol. 1994;91:171-174.
Description: Suggested grading and treatment of patients with acute leukemia and tumor lysis syndrome. PubMed citation number: 7976113
Tumour lysis syndrome: new therapeutic strategies and classification.
Cairo MS, Bishop M.
Br J Haematol. 2004;127:3-11.
Description: Review discussing the incidence of, pathophysiology of, and risk factors for tumor lysis syndrome, as well as a summary of treatment recommendations and a new classification schema.
PubMed citation number: 15384972
Incidence and pathogenesis of tumor lysis syndrome.
Locatelli F, Rossi F.
Contrib Nephrol. 2005;147:61-68.
Description: Review describing the pathogenesis and clinical manifestations of tumor lysis syndrome as well as risk factors for its development.
PubMed citation number: 15604606
Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma.
Stapleton FB, Strother DR, Roy S 3rd, Wyatt RJ, McKay CP, Murphy SB.
Pediatrics. 1988;82:863-869.
Description: Discussion of the management of tumor lysis syndrome in pediatric Burkitt lymphoma or B-cell ALL based on analysis of 40 patients.
PubMed citation number: 3186376
Treatment
Allopurinol: intravenous use for prevention and treatment of hyperuricemia.
Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA.
J Clin Oncol. 2000;18:1758-1763.
Description: Summary of data from a 21-year period to evaluate the efficacy and safety of the use of intravenous allopurinol for the treatment of tumor lysis syndrome.
PubMed citation number: 10764437
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B, Mounier N, Bologna S, et al: Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma.
J Clin Oncol. 2003;21:4402-4406.
Description: Study of the safety and efficacy of recombinant urate oxidase (rasburicase) to prevent and treat tumor lysis syndrome and hyperuricemia in 100 patients undergoing chemotherapy for aggressive NHL. The authors conclude that “rasburicase is the treatment of choice to control UA and prevent tumor lysis syndrome in adult patients with aggressive NHL.”
PubMed citation number: 14581437
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome: a Meeting Report, Dallas, Texas, January 2002.
Navolanic PM, Pui CH, Larson RA, et al.
Leukemia. 2003;17:499-514.
Description: Discussion of the pathophysiology of tumor lysis syndrome in oncology and the mechanism of action and therapeutic role of the new agent recombinant urate oxidase (rasburicase). Summary of expert panel discussion with several example cases.
PubMed citation number: 12646938
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Ribeiro RC, Pui CH.
Clin Lymphoma. 2003;3:225-232.
Description: Overview of hyperuricemia and tumor lysis syndrome in lymphoid malignancies and the role of rasburicase in their management.
PubMed citation number: 12672271
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC, Holcenberg JS, Finklestein JZ, et al.
Blood. 2001;97:2998-3003.
Description: Multicenter randomized trial of rasburicase versus allopurinol in pediatric patients with leukemia and lymphoma at high risk for tumor lysis syndrome. The authors conclude that the rasburicase group had lower levels of plasma uric acid, and that it is a safe and effective alternative to allupurinol in this population.
PubMed citation number: 11342423
Review
Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.
Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ.
Am J Med. 2004;116:546-554.
Description: Review of tumor lysis syndrome with an emphasis on treatment, including discussion of rasburicase. PubMed citation number: 15063817
Tumor lysis syndrome.
Jeha S.
Semin Hematol. 2001;38:4-8.
Description: Comprehensive review of tumor lysis syndrome in adults and children.
PubMed citation number: 11694945
Hyperuricemic syndromes in cancer patients.
Tsimberidou AM, Keating MJ.
Contrib Nephrol. 2005;147:47-60.
Description: Review of MEDLINE articles and published meeting abstracts that focus on the risk factors and underlying pathologies of oncology patients at risk for tumor lysis syndrome or hyperuricemia during chemotherapy treatment.
PubMed citation number: 15604605